Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Despite the jump in the number of teens being prescribed Wegovy, it still represents only a small fraction of kids who are living with obesity. Approximately one in 5 children and teens in the U.S.

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

Almonds, pistachios, and walnuts may help boost GLP-1 thanks to their fiber, protein, and healthy fats. These nutrients work ...

Hangzhou Sciwind Biosciences claims its drug ecnoglutide delivers over 15% weight loss at highest dose after 48 weeks.

“GLP-1 drugs don’t just curb appetite – they dull the desire to drink at a metabolic level. With cravings suppressed and ...

Pharmaceutical companies are taking advantage of the drug patent system to keep prices of essential medications high, ...

If you're the kind of person who thrives on binary rules, pain-driven discipline, and the smug superiority of having ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.